Tinofend®
Research

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Please note that the physiological activity of the ingredient(s) described herein is supported by the referenced clinical trial reports. Marketers of finished products containing the ingredient(s) described herein are responsible for determining whether claims made for such products are lawful and in compliance with the laws of the country in which they will market the products.

Tinofend®
Research

Tinofend®
Research

  • Filter Research By Type:

  • Filter Research By Dosage:

Don’t see what you’re looking for? All additional research is categorized under supportive research.

Efficacy of Tinospora Cordifolia on thermal burn patients.

Gangrade G et al.
Indian Med Gazette: Alter Med. 140(1): 38-43.
Immune compromization is known to occur in burn patients, thus, 300mg Tinofend® thrice daily was administered to evaluate potential immunostimulant properties. Tinofend was well tolerated and no adverse effects were noted. Tinofend® exhibited immune supporting properties that are further supportive of historical application and clinical evidence.

Tinospora cordifolia: A review of its immunomodulatory properties.

Yates CR et al.
J Diet Supp. 2021 Jan 22. (2021). Review paper. doi: 10.1080/19390211.2021.1873214
A review paper which mentions Tinofend's research within.

Chemistry and Pharmacology of Tinospora Cordifolia.

Singh, D and PK Chaudhuri.
Nat Prod Com. 2017. 12(2): 299-308. doi: 10.1177/1934578x1701200240
A review of the chemistry and pharmacology of Tinospora cordifolia. The authors conclude, “the biological study and clinical trials of T cordifolia are indicative of its safety and potent therapeutic value as a health supplement of commercial importance, as well as a store house for future drug development in critical diseases where modern medicines have limited therapeutic potential.”

Immunmodulatory role of Tinospora cordifolia as an adjuvant in surgical treatment of foot ulcers: A prospective randomized controlled trial.

Purandare H et al.
Ind J Med Sci. 2007 Jun. 61(6). 347-355.
A prospective double-blind randomized controlled study lasting 18 months in 50 patients investigated the effects of T cordifolia as an adjuvant therapy, and it was found that diabetic patients with foot ulcers in the study group showed significantly better final outcome with improvement in wound healing. Also, immunomodulatory effects were indicated due to reduced debridement and improved phagocytosis.

Scientific validation of the medicinal efficacy of Tinospora cordifolia.

Mishra A et al.
Sci World J. 2013 Aug 31. 2103(Art ID 292934): 8pgs. doi: 10.1155/2013/292934
This study performed multiple assays to test for antibacterial, antioxidant, and anticancer activity in T cordifolia, and the results were promising; remarkable potential for all three actions was discovered/reinforced.

Efficacy and safety of Tinospora cordifolia lotion in pediatric patients: A Single blind, randomized controlled trial.

Castillo et al.
J Pharmacol Pharmacother. 2013. 4(1): 39-46.
A single blind, randomized, controlled pilot study to investigate clinical efficacy of T. cordifolia lotion in 66 patients with scabies in comparison with permethrin lotion. Both lotions significantly reduced the mean global evaluation score after 4 weeks of treatment, and they showed comparable effects; subsequently, T cordifolia’s incorporation as a therapeutic reagent in scabies infection is highly recommended by the authors.

Tinospora cordifolia: One plant, many roles.

Saha S and S Ghosh.
Ancient Sci Life. 2012 Apr-Jun. 31(4): 151-159. doi: 10.4103/0257-7941.107344
This review goes over the genetic diversity of T cordifolia and the active constituents of the plant and their role in disease targeting. A myriad of biologically active compounds are contained in the plant, with various roles and actions.

Herbal medicines for the treatment of allergic rhinitis: A systematic review.

Guo R, PhD et al.
Ann Allergy Asthma Immunol. 2007 Dec. 99(6): 483-495. Review paper. doi: 10.1016/S1081-1206(10)60375-4
A review paper with mention of Tinofend extract within.

Short-term effect of Tinospora cordifolia [Tinofend®] in allergic rhinitis.

Thawani et al.
The Antiseptic. 2006 Apr. Vol 3(No 4). 229-232.
A randomized, double-blind, placebo controlled trial in subjects with allergic rhinitis (AR), Tinofend® was shown to significantly improve symptoms commonly associated with AR within 15 days, with further improvements in an additional 15 days. Tinofend was well tolerated, and no adverse events were reported.

Tinospora cordifolia as an adjuvant drug in treatment of patients--case reports.

Singh RK.
J Vector Borne Dis. 2005 Mar. 42(1): 36-38.
Three separate cases of hyper-reactive malarious splenomegaly who were previously slow responding to the conventional antimalarial drug, chloroquine. An aqueous extract of T cordifolia (500mg) was added to chloroquine base (300mg) weekly and CQ prophylaxis was observed up to six months. Addition of the extract for the first six weeks showed regression of the spleen, decrease in serum IgM, and increase in Hb and wellbeing (Karnofsky performance scale).

Efficacy of Tinospora cordifolia [Tinofend®] in allergic rhinitis.

Badar VA et al.
J Ethnopharmacol. 2005 Jan 15. Vol 96(Issue 3): 445-449. doi: 10.1016/j.jep.2004.09.034
A randomized, double-blind, placebo controlled trial in subjects with hay fever (allergic rhinitis), Tinofend® stimulated the activity of white blood cells that regulate the immune response and reduced the number of eosinophils (immune cells which release histamine). It was reported that Tinofend was well tolerated.

Immunotherapy with Tinospora cordifolia: A new lead in the management of obstructive jaundice.

Rege et al.
Ind J Gastroenterol. 1993 Jan. 12(1): 5-8.